Avutometinib and defactinib: a novel dual pathway inhibition strategy for recurrent KRAS-mutant low-grade serous ovarian cancer

Sarah Hayward; Cassidy Blaiss; Erin Hickey Zacholski; Jennifer MacDonald

doi:10.1016/j.ijgc.2026.104635

March 1, 2026International Journal of Gynecological CancerOpen Access

Avutometinib and defactinib: a novel dual pathway inhibition strategy for recurrent KRAS-mutant low-grade serous ovarian cancer

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the efficacy and tolerability of the combination therapy of avutometinib and defactinib in treating recurrent KRAS-mutant low-grade serous ovarian cancer.
Literature review of clinical trial data
Discussion on the pharmacology of avutometinib and defactinib
Analysis of adverse event management
Combination therapy demonstrated meaningful efficacy with clinically significant response rates.
Manageable adverse events were reported, indicating a favorable safety profile.
The therapy received FDA accelerated approval and was included in the National Comprehensive Cancer Network guidelines.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

This literature review showcases efficacy of a dual therapy in recurrent KRAS-mutated low-grade serous ovarian cancer, suggesting a path for personalized treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hayward et al. (2026) studied this question.

synapsesocial.com/papers/69b3aaa802a1e69014ccb726 https://doi.org/10.1016/j.ijgc.2026.104635

View Full Paper

Ask AI

Bookmark

Share

Avutometinib and defactinib: a novel dual pathway inhibition strategy for recurrent KRAS-mutant low-grade serous ovarian cancer

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Avutometinib and defactinib: a novel dual pathway inhibition strategy for recurrent KRAS-mutant low-grade serous ovarian cancer

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading